rs74315364
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP6BS2
The NM_021133.4(RNASEL):c.793G>T(p.Glu265Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00369 in 1,614,092 control chromosomes in the GnomAD database, including 19 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_021133.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RNASEL | NM_021133.4 | c.793G>T | p.Glu265Ter | stop_gained | 2/7 | ENST00000367559.7 | NP_066956.1 | |
RNASEL | XM_047427096.1 | c.793G>T | p.Glu265Ter | stop_gained | 2/7 | XP_047283052.1 | ||
RNASEL | XM_047427106.1 | c.793G>T | p.Glu265Ter | stop_gained | 2/6 | XP_047283062.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RNASEL | ENST00000367559.7 | c.793G>T | p.Glu265Ter | stop_gained | 2/7 | 1 | NM_021133.4 | ENSP00000356530 | P1 | |
RNASEL | ENST00000539397.1 | c.793G>T | p.Glu265Ter | stop_gained | 2/6 | 2 | ENSP00000440844 |
Frequencies
GnomAD3 genomes AF: 0.00325 AC: 495AN: 152184Hom.: 3 Cov.: 32
GnomAD3 exomes AF: 0.00362 AC: 901AN: 249190Hom.: 2 AF XY: 0.00377 AC XY: 508AN XY: 134824
GnomAD4 exome AF: 0.00373 AC: 5453AN: 1461790Hom.: 16 Cov.: 35 AF XY: 0.00374 AC XY: 2722AN XY: 727196
GnomAD4 genome AF: 0.00326 AC: 496AN: 152302Hom.: 3 Cov.: 32 AF XY: 0.00314 AC XY: 234AN XY: 74468
ClinVar
Submissions by phenotype
Prostate cancer, hereditary, 1 Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 26, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2002 | - - |
not provided Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 31, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2023 | RNASEL: BS1, BS2 - |
Malignant tumor of prostate Pathogenic:1
Likely pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NM_021133.3:c.793G>T in the RNASEL gene has an allele frequency of 0.008 in European (Finnish) subpopulation in the gnomAD database. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.793G>T(p.Glu265*) was segregated in four affected brothers from a family suffering from prostate canser (PMID: 11799394). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PVS1, PP1_Moderate. - |
RNASEL-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 11, 2023 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at